In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark Age predecessors, living until ripe old age and enjoying the fruits of our ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest ...

We expect investors to focus on the sales performance of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other pipeline updates when the company reports its second-quarter 2025 results.

If you have been staring at CRISPR Therapeutics stock lately, wondering whether it is time to buy, hold, or rethink your position, you are far from alone. Over the past week, the stock has surged 16.1 ...

There was a lot of hype and excitement around gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) last year after it obtained approval for its first product, Casgevy. But that excitement has ...